1193 related articles for article (PubMed ID: 24331747)
1. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa.
Sankaranarayanan R; Anorlu R; Sangwa-Lugoma G; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F47-52. PubMed ID: 24331747
[TBL] [Abstract][Full Text] [Related]
2. Trials and projects on cervical cancer and human papillomavirus prevention in sub-Saharan Africa.
Adefuye PO; Broutet NJ; de Sanjosé S; Denny LA
Vaccine; 2013 Dec; 31 Suppl 5():F53-9. PubMed ID: 24331748
[TBL] [Abstract][Full Text] [Related]
3. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa.
Kim JJ; Campos NG; O'Shea M; Diaz M; Mutyaba I
Vaccine; 2013 Dec; 31 Suppl 5():F60-72. PubMed ID: 24331749
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
5. Model-based impact and cost-effectiveness of cervical cancer prevention in the Extended Middle East and North Africa (EMENA).
Kim JJ; Sharma M; O'Shea M; Sweet S; Diaz M; Sancho-Garnier H; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G65-77. PubMed ID: 24331822
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.
Rogovskaya SI; Shabalova IP; Mikheeva IV; Minkina GN; Podzolkova NM; Shipulina OY; Sultanov SN; Kosenko IA; Brotons M; Buttmann N; Dartell M; Arbyn M; Syrjänen S; Poljak M
Vaccine; 2013 Dec; 31 Suppl 7():H46-58. PubMed ID: 24332297
[TBL] [Abstract][Full Text] [Related]
7. Implementation of human papillomavirus immunization in the developing world.
Kane MA; Serrano B; de Sanjosé S; Wittet S
Vaccine; 2012 Nov; 30 Suppl 5():F192-200. PubMed ID: 23199963
[TBL] [Abstract][Full Text] [Related]
8. Prospects and challenges in the introduction of human papillomavirus vaccines in the extended Middle East and North Africa region.
Jumaan AO; Ghanem S; Taher J; Braikat M; Al Awaidy S; Dbaibo GS
Vaccine; 2013 Dec; 31 Suppl 6():G58-64. PubMed ID: 24331821
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility analysis of interventions to reduce the burden of cervical cancer in Israel.
Ginsberg GM
Vaccine; 2013 Nov; 31 Suppl 8():I46-52. PubMed ID: 24229719
[TBL] [Abstract][Full Text] [Related]
10. Cervical cancer screening, human papillomavirus vaccination practices and current infrastructure in Israel.
Schejter E; Bornstein J; Siegler E
Vaccine; 2013 Nov; 31 Suppl 8():I42-5. PubMed ID: 24229718
[TBL] [Abstract][Full Text] [Related]
11. Reframing cervical cancer prevention. Expanding the field towards prevention of human papillomavirus infections and related diseases.
Bosch FX; Tsu V; Vorsters A; Van Damme P; Kane MA
Vaccine; 2012 Nov; 30 Suppl 5():F1-11. PubMed ID: 23199951
[TBL] [Abstract][Full Text] [Related]
12. Overview of cervical cancer screening practices in the extended Middle East and North Africa countries.
Sancho-Garnier H; Khazraji YC; Cherif MH; Mahnane A; Hsairi M; El Shalakamy A; Osgul N; Tuncer M; Jumaan AO; Seoud M
Vaccine; 2013 Dec; 31 Suppl 6():G51-7. PubMed ID: 24331820
[TBL] [Abstract][Full Text] [Related]
13. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges.
Poljak M
Clin Microbiol Infect; 2012 Oct; 18 Suppl 5():64-9. PubMed ID: 22862799
[TBL] [Abstract][Full Text] [Related]
15. Upgrading public health programs for human papillomavirus prevention and control is possible in low- and middle-income countries.
Steben M; Jeronimo J; Wittet S; Lamontagne DS; Ogilvie G; Jensen C; Smith J; Franceschi S
Vaccine; 2012 Nov; 30 Suppl 5():F183-91. PubMed ID: 23199962
[TBL] [Abstract][Full Text] [Related]
16. Human papillomavirus vaccine introduction--the first five years.
Markowitz LE; Tsu V; Deeks SL; Cubie H; Wang SA; Vicari AS; Brotherton JM
Vaccine; 2012 Nov; 30 Suppl 5():F139-48. PubMed ID: 23199957
[TBL] [Abstract][Full Text] [Related]
17. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
[TBL] [Abstract][Full Text] [Related]
18. Barriers to human papillomavirus vaccine acceptability in Israel.
Fisher WA; Laniado H; Shoval H; Hakim M; Bornstein J
Vaccine; 2013 Nov; 31 Suppl 8():I53-7. PubMed ID: 24229720
[TBL] [Abstract][Full Text] [Related]
19. HPV testing and vaccination in Europe.
Leeson SC; Alibegashvili T; Arbyn M; Bergeron C; Carriero C; Mergui JL; Nieminen P; Prendiville W; Redman CW; Rieck GC; Quaas J; Petry KU
J Low Genit Tract Dis; 2014 Jan; 18(1):61-9. PubMed ID: 23774078
[TBL] [Abstract][Full Text] [Related]
20. The burden of human papillomavirus infections and related diseases in sub-saharan Africa.
De Vuyst H; Alemany L; Lacey C; Chibwesha CJ; Sahasrabuddhe V; Banura C; Denny L; Parham GP
Vaccine; 2013 Dec; 31 Suppl 5(0 5):F32-46. PubMed ID: 24331746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
